NetworkNewsBreaks – Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) Meets Phase 1 Portion of Intratumoral IMO-2125 Combination Trial, Begins Enrolling Phase 2 Trial
Idera Pharmaceuticals (NASDAQ: IDRA) this morning announced the successful completion of the phase 1 portion of the ongoing phase 1/2 clinical trial of intratumoral IMO-2125 for the treatment of anti-PD-1 refractory metastatic melanoma. Enrollment has commenced for the phase 2 portion of the trial, and Idera expects to have overall response rate (ORR) data available in the first quarter of 2018. “There is a very clear unmet medical need for those patients for whom current checkpoint inhibitor therapies are not providing adequate solutions. We are incredibly focused on advancing this program as rapidly as possible for these patients, and we…







